SCHEMBL8285284

SCHEMBL8285284

CCC(=O)N1CCN(c2cc3c(cn2)c(=O)cc(Nc2ccccc2)n3-c2ccccc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.45
SKP1 P63208 2/20 0.45
SKP2 Q13309 2/20 0.45
MAPT P10636 4/20 0.40
PDE11A Q9HCR9 1/20 0.39
P2RY12 Q9H244 1/20 0.38
SYK P43405 3/20 0.37
NAMPT P43490 1/20 0.37
KMT2A Q03164 1/20 0.37
ME2 P23368 3/20 0.37
ME1 P48163 3/20 0.37
ME3 Q16798 3/20 0.37
KDM4E B2RXH2 1/20 0.37
LOXL2 Q9Y4K0 1/20 0.36
BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8287220 0.90 CKS1B (0.41) CKS1BSKP1SKP2MAPTPDE11A
SCHEMBL8287528 0.89 P2RY12 (0.44) MAPTP2RY12KMT2AKDM4E
SCHEMBL8287468 0.89 P2RY12 (0.41) MAPTPDE11AP2RY12KMT2AKDM4E
SCHEMBL8285256 0.87 CKS1B (0.44) CKS1BSKP1SKP2MAPTPDE11A
SCHEMBL8287232 0.87 MAPT (0.43) CKS1BSKP1SKP2MAPTPDE11A
SCHEMBL8287497 0.86 PDE11A (0.46) MAPTPDE11AKMT2AKDM4E
SCHEMBL8361778 0.86 CDK4 (0.43) PDE11A
SCHEMBL8285282 0.85 ALDH1A1 (0.42) MAPTPDE11AKMT2AKDM4E
SCHEMBL8286467 0.84 PDE11A (0.44) MAPTPDE11AKDM4E
SCHEMBL8287210 0.83 PDE11A (0.43) MAPTPDE11AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005091857-A2 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2005-10-06 WO disclosed
WO-2003027112-A1 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed